Peroxisome proliferator-activated receptor-γ and its role in the development and treatment of diabetes

Experimental Diabesity Research

Volumn 5, Issue 2, 2004, Pages 99-109

  Leff, Todd ^a,b   Mathews, Suresh T ^a,b   Camp, Heidi S ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Adipocyte; Diabetes; Gene expression; Nuclear receptors; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DRUG RECEPTOR; GLUCOSE; INSULIN; LAMININ; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; ROSIGLITAZONE;

ADIPOCYTE; CELL DIFFERENTIATION; CELL MATURATION; DRUG MECHANISM; DRUG RESEARCH; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC POLYMORPHISM; GLUCOSE HOMEOSTASIS; HETEROZYGOSITY; HUMAN; INSULIN RESISTANCE; LIPODYSTROPHY; MEDICAL RESEARCH; METABOLIC REGULATION; MOLECULAR MECHANICS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; RECEPTOR UPREGULATION; REVIEW; CYTOLOGY; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADIPOCYTES; CELL DIFFERENTIATION; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; OBESITY; PPAR GAMMA;

EID: 16544393025     PISSN: 15438600     EISSN: None     Source Type: Journal    
DOI: 10.1080/15438600490451668     Document Type: Review

References (82)

1. Kliewer, S. A., Xu, H. E., Lambert, M. H., and Willson, T. M. (2001) Peroxisome proliferator-activated receptors: From genes to physiology. Recent Prog. Horm. Res., 56, 239-263.
2. Michalik, L., and Wahli, W. (1999) Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions. Curr. Opin. Biotechnol., 10, 564-570.
3. Dreyer, C., Keller, H., Mahfoudi, A., Laudet, V., Krey, G., and Wahli, W. (1993) Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol. Cell, 77, 67-76.
4. Forman, B. M., Chen, J., and, Evans, R. M. (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U.S.A., 94, 4312-4317.
5. Krey, G., Braissant, O., L'Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., and Wahli, W. (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol., 11, 779-791.
6. Peters, J. M., Lee, S. S., Li, W., Ward, J. M., Gavrilova, O., Everett, C., Reitman, M. L., Hudson, L. D., and Gonzalez, F. J. (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol. Cell. Biol., 20, 5119-5128.
7. Michalik, L., Desvergne, B., Tan, N. S., Basu-Modak, S., Escher, P., Rieusset, J., Peters, J. M., Kaya, G., Gonzalez, F. J., Zakany, J., Metzger, D., Chambon, P., Duboule, D., and Wahli, W. (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J. Cell. Biol., 154, 799-814.
8. Oliver, W. R., Jr., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., Xu, H. E., Sternbach, D. D., Kliewer, S. A., Hansen, B. C., and Wilson, T. M. (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A., 98, 5306-5311.
9. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953-12956.
10. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 391, 79-82.
11. Jiang, C., Ting, A. T., and Seed, B. (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 391, 82-86.
12. Plutzky, J. (2001) Peroxisome proliferator-activated receptors in endothelial cell biology. Curr. Opin. Lipidol., 12, 511-518.
13. Yang, X. Y., Wang, L. H., Chen, T., Hodge, D. R., Resau, J. H., DaSilva, L., and Farrar, W. L. (2000) Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J. Biol. Chem., 275, 4541-4544.
14. Xu, L., Glass, C. K., and Rosenfeld, M. G. (1999) Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet. Dev., 9, 140-147.
15. Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., and Spiegelman, B. M. (1994) mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev., 8, 1224-1234.
16. Tontonoz, P., Hu, E., and Spiegelman, B. M. (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell, 79, 1147-1156.
17. Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R., Koder, A., and Evans, R. M. (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell., 4, 585-595.
18. Rosen, E. D., and Spiegelman, B. M. (2000) Molecular regulation of adipogenesis. Annu. Rev. Cell. Dev. Biol., 16, 145-171.
19. Darlington, G. J., Ross, S. E., and MacDougald, O. A. (1998) The role of C/EBP genes in adipocyte differentiation. J. Biol. Chem., 273, 30057-30060.
20. Tanaka, T., Yoshida, N., Kishimoto, T., and Akira, S. (1997) Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J., 16, 7432-7443.
21. Ren, D., Collingwood, T. N., Rebar, E. J., Wolffe, A. P., and Camp, H. S. (2002) PPARgamma knockdown by engineered transcription factors: Exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev., 16, 27-32.
22. Wu, Z., Rosen, E. D., Brun, R., Hauser, S., Adelmant, G., Troy, A. E., McKeon, C., Darlington, G. J., and Spiegelman, B. M. (1999) Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol. Cell, 3, 151-158.
23. Wang, N. D., Finegold, M. J., Bradley, A., Ou, C. N., Abdelsayed, S. V., Wilde, M. D., Taylor, L. R., Wilson, D. R., and Darlington, G. J. (1995) Impaired energy homeostasis in C/EBP alpha knockout mice. Science, 269, 1108-1112.
24. Freytag, S. O., Paielli, D. L., and Gilbert, J. D. (1994) Ectopic expression of the CCAAT/enhancer-binding protein alpha promotes the adipogenic program in a variety of mouse fibroblastic cells. Genes. Dev., 8, 1654-1663.
25. Rosen, E. D., Hsu, C. H., Wang, X., Sakai, S., Freeman, M. W., Gonzalez, F. J., and Spiegelman, B. M. (2002) C/EBPalpha induces adipogenesis through PPARgamma: A unified pathway. Genes Dev., 16, 22-26.
26. Ristow, M., Muller-Wieland, D., Pfeiffer, A., Krone, W., and Kahn, C. R. (1998) Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med., 339, 953-959.
27. Barroso, I., Gurnell, M., Crowley, V. E., Agostini, M., Schwabe, J. W., Soos, M. A., Maslen, G. L., Williams, T. D., Lewis, H., Schafer, A. J., Chatterjee, V. K., and O'Rahilly, S. (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature, 402, 880-883.
28. Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T., and Leff, T. (2002) PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes, 51, 3586-3590.
29. Agarwal, A. K. and Garg, A. (2002) A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab., 87, 408-411.
30. Savage, D. B., Agostini, M., Barroso, I., Gurnell, M., Luan, J., Meirhaeghe, A., Harding, A. H., Ihrke, G., Rajanayagam, O., Soos, M. A., George, S., Berger, D., Thomas, E. L., Bell, J. D., Meeran, K., Ross, R. J., Vidal-Puig, A., Wareham, N. J., O'Rahilly, S., Chatterjee, V. K., and Schafer, A. J. (2002) Digenic inheritance of severe insulin resistance in a human pedigree. Nat. Genet., 31, 379-384.
31. Yen, C. J., Beamer, B. A., Negri, C., Silver, K., Brown, K. A., Yarnall, D. P., Burns, D. K., Roth, J., and Shuldiner, A. R. (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: Identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun., 241, 270-274.
32. Deeb, S. S., Fajas, L., Nemoto, M., Pihlajamaki, J., Mykkanen, L., Kuusisto, J., Laakso, M., Fujimoto, W., and Auwerx, J. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet., 20, 284-287.
33. Hamann, A., Munzberg, H., Buttron, P., Busing, B., Hinney, A., Mayer, H., Siegfried, W., Hebebrand, J., and Greten, H. (1999) Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects. Eur. J. Endocrinol., 141, 90-92.
34. Clement, K., Hercberg, S., Passinge, B., Galan, P., Varroud-Vial, M., Shuldiner, A. R., Beamer, B. A., Charpentier, G., Guy-Grand, B., Froguel, P., and Vaisse, C. (2000) The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int. J. Obes. Relat. Metab. Disord., 24, 391-393.
35. Beamer, B. A., Yen, C. J., Andersen, R. E., Muller, D., Elahi, D., Cheskin, L. J., Andres, R., Roth, J., and Shuldiner, A. R. (1998) Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes, 47, 1806-1808.
36. Cole, S. A., Mitchell, B. D., Hsueh, W. C., Pineda, P., Beamer, B. A., Shuldiner, A. R., Comuzzie, A. G., Blangero, J., and Hixson, J. E. (2000) The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int. J. Obes. Relat. Metab. Disord., 24, 522-524.
37. Valve, R., Sivenius, K., Miettinen, R., Pihlajamaki, J., Rissanen, A., Deeb, S. S., Auwerx, J., Uusitupa, M., and Laakso, M. (1999) Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J. Clin. Endocrinol. Metab., 84, 3708-3712.
38. Stumvoll, M., and Haring, H. (2002) The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes, 51, 2341-2347.
39. Altshuler, D., Hirschhorn, J. N., Klannemark, M., Lindgren, C. M., Vohl, M. C., Nemesh, J., Lane, C. R., Schaffner, S. F., Bolk, S., Brewer, C., Tuomi, T., Gaudet, D., Hudson, T. J., Daly, M., Groop, L., and Lander, E. S. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet., 26, 76-80.
40. Hegele, R. A. (2000) Familial partial lipodystrophy: A monogenic form of the insulin resistance syndrome. Mol. Genet. Metab., 71, 539-544.
41. Cao, H., and Hegele, R. A. (2000) Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet., 9, 109-112.
42. Shackleton, S., Lloyd, D. J., Jackson, S. N., Evans, R., Niermeijer, M. F., Singh, B. M., Schmidt, H., Brabant, G., Kumar, S., Durrington, P. N., Gregory, S., O'Rahilly, S., and Trembath, R. C. (2000) LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat. Genet., 24, 153-156.
43. Speckman, R. A., Garg, A., Du, F., Bennett, L., Veile, R., Arioglu, E., Taylor, S. I., Lovett, M., and Bowcock, A. M. (2000) Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. Am. J. Hum. Genet., 66, 1192-1198.
44. Agostini, M., Gurnell, M., Savage, D. B., Wood, E. M., Smith, A. G., Rajanayagam, O., Garnes, K. T., Levinson, S. H., Xu, H. E., Schwabe, J. W., Willson, T. M., O'Rahilly, S., and Chatterjee, V. K. (2003) Tyrosine agonists reverse the molecular defects associated with dominant negative mutations in human PPAR gamma. Endocrinology, 145, 1527-1538.
45. Savage, D. B., Tan, G. D., Acerini, C. L., Jebb, S. A., Agostini, M., Gurnell, M., Williams, R. L., Umpleby, A. M., Thomas, E. L., Bell, J. D., Dixon, A. K., Dunne, F., Boiani, R., Cinti, S., Vidal-Puig, A., Karpe, F., Chatterjee, V. K., and O'Rahilly, S. (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes, 52, 910-917.
46. Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., and Milburn, M. V. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature, 395, 137-143.
47. Miles, P. D., Barak, Y., He, W., Evans, R. M., and Olefsky, J. M. (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest., 105, 287-292.
48. Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., Eto, K., Tsubamoto, Y., Okuno, A., Murakami, K., Sekihara, H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., Shiota, K., Kitamura, T., Fujita, T., Ezaki, O., Aizawa, S., Kadowaki, T., et al. (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell, 4, 597-609.
49. Hu, E., Kim, J. B., Sarraf, P., and Spiegelman, B. M. (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science, 274, 2100-2103.
50. Camp, H. S., and Tafuri, S. R. (1997) Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J. Biol. Chem., 272, 10811-10816.
51. Rangwala, S. M., Rhoades, B., Shapiro, J. S., Rich, A. S., Kim, J. K., Shulman, G. I., Kaestner, K. H., and Lazar, M. A. (2003) Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev. Cell, 5, 657-663.
52. Shuldiner, A. R., Nguyen, W., Kao, W. H., Beamer, B. A., Andersen, R. E., Pratley, R., and Brancati, F. L. (2000) Pro115Gln peroxisome proliferator-activated receptor-gamma and obesity. Diabetes Care, 23, 126-127.
53. Schaffler, A., Barth, N., Schmitz, G., Zietz, B., Palitzsch, K. D., and Scholmerich, J. (2001) Frequency and significance of Pro12Ala and Pro115Gln polymorphism in gene for peroxisome proliferation-activated receptor-gamma regarding metabolic parameters in a Caucasian cohort. Endocrine, 14, 369-373.
54. Hamer, O. W., Forstner, D., Ottinger, I., Ristow, M., Bollheimer, L. C., Scholmerich, J., and Palitzsch, K. D. (2002) The Pro115Gln polymorphism within the PPAR gamma2 gene has no epidemiological impact on morbid obesity. Exp. Clin. Endocrinol. Diabetes, 110, 230-234.
55. Bluher, M., and Paschke, R. (2003) Analysis of the relationship between PPAR-gamma 2 gene variants and severe insulin resistance in obese patients with impaired glucose tolerance. Exp. Clin. Endocrinol. Diabetes, 111, 85-90.
56. Olansky, L., Marchetti, A., and Lau, H. (2003) Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels. Clin. Ther., 25(Suppl B), B64-B80.
57. Kletzien, R. F., Clarke, S. D., and Ulrich, R. G. (1992) Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol., 41, 393-398.
58. Chawla, A., Schwarz, E. J., Dimaculangan, D. D., and Lazar, M. A. (1994) Peroxisome proliferator-activated receptor (PPAR) gamma: Adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology, 135, 798-800.
59. Spiegelman, B. M. (1998) PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes, 47, 507-514.
60. Cobb, J. E., Blanchard, S. G., Boswell, E. G., Brown, K. K., Charifson, P. S., Cooper, J. P., Collins, J. L., Dezube, M., Henke, B. R., Hull-Ryde, E. A., Lake, D. H., Lenhard, J. M., Oliver, W., Jr., Oplinger, J., Pentti, M., Parks, D. J., Plunket, K. D., and Tong, W. Q. (1998) N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41, 5055-5069.
61. Burant, C. F., Sreenan, S., Hirano, K., Tai, T. A., Lohmiller, J., Lukens, J., Davidson, N. O., Ross, S., and Graves, R. A. (1997) Troglitazone action is independent of adipose tissue. J. Clin. Invest., 100, 2900-2908.
62. Chao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Axioglu, E., Gavrilova, O., and Reitman, M. L. (2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest., 106, 1221-1228.
63. Hevener, A. L., He, W., Barak, Y., Le, J., Bandyopadhyay, G., Olson, P., Wilkes, J., Evans, R. M., and Olefsky, J. (2003) Muscle-specific Pparg deletion causes insulin resistance. Nat. Med., 9, 1491-1497.
64. Norris, A. W., Chen, L., Fisher, S. J., Szanto, I., Ristow, M., Jozsi, A. C., Hirshman, M. F., Rosen, E. D., Goodyear, L. J., Gonzalez, F. J., Spiegelman, B. M., and Kahn, C. R. (2003) Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest., 112, 608-618.
65. Unger, R. H. (2002) Lipotoxic diseases. Annu. Rev. Med., 53, 319-336.
66. Yamauchi, T., Kamon, J., Waki, H., Murakami, K., Motojima, K., Korneda, K., Ide, T., Kubota, N., Terauchi, Y., Tobe, K., Miki, H., Tsuchida, A., Akanuma, Y., Nagai, R., Kimura, S., and Kadowaki, T. (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem., 276, 41245-41254.
67. Okuno, A., Tamemoto, H., Tobe, K., Ueki, K., Mori, Y., Iwamoto, K., Umesono, K., Akanuma, Y., Fujiwara, T., Horikoshi, H., Yazaki, Y., and Kadowaki, T. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101, 1354-1361.
68. de Souza, C. J., Eckhardt, M., Gagen, K., Dong, M., Chen, W., Laurent, D., and Burkey, B. F. (2001) Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes, 50, 1863-1871.
69. Akazawa, S., Sun, F., Ito, M., Kawasaki, E., and Eguchi, K. (2000) Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care, 23, 1067-1071.
70. Mori, Y., Murakawa, Y., Okada, K., Horikoshi, H., Yokoyama, J., Tajima, N., and Ikeda, Y. (1999) Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care, 22, 908-912.
71. Giusti, V., Verdumo, C., Suter, M., Gaillard, R. C., Burckhardt, P., and Pralong, F. (2003) Expression of peroxisome proliferator-activated receptor-gamma1 and peroxisome proliferator-activated receptor-gamma2 in visceral and subcutaneous adipose tissue of obese women. Diabetes, 52, 1673-1676.
72. Tsao, T. S., Lodish, H. F., and Fruebis, J. (2002) ACRP30, a new hormone controlling fat and glucose metabolism. Eur. J. Pharmacol., 440, 213-221.
73. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y, Gavrilova, O., Vinson, C., Reitman, M. L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe, K., Nagai, R., Kimura, S., Tomita, M., Froguel, P., and Kadowaki, T. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 7, 941-946.
74. Berg, A. H., Combs, T. P., Du, X., Brownlee, M., and Scherer, P. E. (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med., 7, 947-953.
75. Fruebis, J., Tsao, T. S., Javorschi, S., Ebbets-Reed, D., Erickson, M. R., Yen, F. T., Bihain, B. E., and Lodish, H. F. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U.S.A., 98, 2005-2010.
76. Steppan, C. M., and Lazar, M. A. (2002) Resistin and obesity-associated insulin resistance. Trends Endocrinol. Metab., 13, 18-23.
77. Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., and Lazar, M. A. (2001) The hormone resistin links obesity to diabetes. Nature, 409, 307-312.
78. Way, J. M., Gorgun, C. Z., Tong, Q., Uysal, K. T., Brown, K. K., Harrington, W. W., Oliver, W. R., Jr., Willson, T. M., Kliewer, S. A., and Hotamisligil, G. S. (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem., 276, 25651-25653.
79. Savage, D. B., Sewter, C. P., Klenk, E. S., Segal, D. G., Vidal-Puig, A., Considine, R. V., and O'Rahilly, S. (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes, 50, 2199-2202.
80. Hotamisligil, G. S., Shargill, N. S., and Spiegelman, B. M. (1993) Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science, 259, 87-91.
81. Moller, D. E. (2000) Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol. Metab., 11, 212-217.
82. Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., and Spiegelman, B. M. (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest., 95, 2409-2415.